N/A
Completed N=299
Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)
Source: ClinicalTrials.gov NCT00794118 ↗Enrolled (actual)
299
Serious AEs
0.0%
Results posted
May 2012
Primary outcomePrimary: Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 3 — 13.4 Percentage of participants
Summary
The primary purpose of this observational study is to describe and define the current daily practice of management of anti-TNF-agents in Rheumatoid Arthritis (RA) patients. Data will be collected only from subjects providing informed consent.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 3 |
13.4 | — |
| PRIMARY Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 6 |
21.6 | — |
| PRIMARY Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 9 |
27.2 | — |
| PRIMARY Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 12 |
22.6 | — |
| PRIMARY Disease Activity Score Based on 28-joints Count (DAS28) at Month 3 |
4.2 | — |
| PRIMARY Disease Activity Score Based on 28-joints Count (DAS28) at Month 6 |
3.7 | — |
| PRIMARY Disease Activity Score Based on 28-joints Count (DAS28) at Month 9 |
3.4 | — |
| PRIMARY Disease Activity Score Based on 28-joints Count (DAS28) at Month 12 |
3.6 | — |
| PRIMARY Patient Global Assessment (PtGA) of Disease Activity Score at Month 3 |
4.1 | — |
| PRIMARY Patient Global Assessment (PtGA) of Disease Activity Score at Month 6 |
3.4 | — |
| PRIMARY Patient Global Assessment (PtGA) of Disease Activity Score at Month 9 |
2.8 | — |
| PRIMARY Patient Global Assessment (PtGA) of Disease Activity Score at Month 12 |
3.3 | — |
| PRIMARY Physician Global Assessment (PGA) of Disease Activity at Month 3 |
3.7 | — |
| PRIMARY Physician Global Assessment (PGA) of Disease Activity at Month 6 |
2.9 | — |
| PRIMARY Physician Global Assessment (PGA) of Disease Activity at Month 9 |
2.3 | — |
| PRIMARY Physician Global Assessment (PGA) of Disease Activity at Month 12 |
2.8 | — |
| PRIMARY Visual Analogue Scale for Pain (VAS-pain) at Month 3 |
4.1 | — |
| PRIMARY Visual Analogue Scale for Pain (VAS-pain) at Month 6 |
3.3 | — |
| PRIMARY Visual Analogue Scale for Pain (VAS-pain) at Month 9 |
2.9 | — |
| PRIMARY Visual Analogue Scale for Pain (VAS-pain) at Month 12 |
3.3 | — |
| PRIMARY C-reactive Protein (CRP) at Month 3 |
1.4 | — |
| PRIMARY C-reactive Protein (CRP) at Month 6 |
1.3 | — |
| PRIMARY C-reactive Protein (CRP) at Month 9 |
1.1 | — |
| PRIMARY C-reactive Protein (CRP) at Month 12 |
1.5 | — |
| PRIMARY Erythrocyte Sedimentation Rate (ESR) at Month 3 |
23.9 | — |
| PRIMARY Erythrocyte Sedimentation Rate (ESR) at Month 6 |
20.8 | — |
| PRIMARY Erythrocyte Sedimentation Rate (ESR) at Month 9 |
18.4 | — |
| PRIMARY Erythrocyte Sedimentation Rate (ESR) at Month 12 |
21.9 | — |
| PRIMARY Number of Participants With Rheumatoid Factor (RF) at Month 3 |
80; 88; 98 | — |
| PRIMARY Number of Participants With Rheumatoid Factor (RF) at Month 6 |
77; 74; 83 | — |
| PRIMARY Number of Participants With Rheumatoid Factor (RF) at Month 9 |
63; 57; 106 | — |
| PRIMARY Number of Participants With Rheumatoid Factor (RF) at Month 12 |
88; 67; 117 | — |
| PRIMARY Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 3 |
43; 50; 174 | — |
| PRIMARY Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 6 |
44; 44; 147 | — |
| PRIMARY Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 9 |
32; 39; 154 | — |
| PRIMARY Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 12 |
52; 45; 175 | — |
| PRIMARY Number of Participants With Anti-nuclear Antibodies at Month 3 |
8; 78; 181 | — |
| PRIMARY Number of Participants With Anti-nuclear Antibodies at Month 6 |
14; 79; 142 | — |
| PRIMARY Number of Participants With Anti-nuclear Antibodies at Month 9 |
9; 57; 159 | — |
| PRIMARY Number of Participants With Anti-nuclear Antibodies at Month 12 |
14; 85; 173 | — |
| PRIMARY Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 3 |
1; 79; 187 | — |
| PRIMARY Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 6 |
1; 80; 154 | — |
| PRIMARY Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 9 |
4; 60; 161 | — |
| PRIMARY Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 12 |
3; 88; 181 | — |
| PRIMARY Duration of Morning Stiffness at Month 3 |
26.4 | — |
| PRIMARY Duration of Morning Stiffness at Month 6 |
19.6 | — |
| PRIMARY Duration of Morning Stiffness at Month 9 |
13.2 | — |
| PRIMARY Duration of Morning Stiffness at Month 12 |
17.8 | — |
| PRIMARY Stanford Health Assessment Questionnaire (HAQ) Score at Month 3 |
1.0 | — |
| PRIMARY Stanford Health Assessment Questionnaire (HAQ) Score at Month 6 |
0.7 | — |
| PRIMARY Stanford Health Assessment Questionnaire (HAQ) Score at Month 9 |
0.7 | — |
| PRIMARY Stanford Health Assessment Questionnaire (HAQ) Score at Month 12 |
0.8 | — |
| PRIMARY 36-Item Short-Form Health Survey (SF-36) at Month 12 |
52.2; 55.5 | — |
| SECONDARY Direct Costs |
— | — |
| SECONDARY Indirect Costs |
— | — |
Eligibility Criteria
Inclusion Criteria
- Eighteen years of age or older
- Diagnosis of RA in accordance with ARA 1987 classification has satisfied at least 4 of the following 7 criteria:
- Morning stiffness in and around the joints lasting at least 1 hour;
- Arthritis of 3 or more joint areas;
- Arthritis of hand joints;
- Symmetric arthritis. simultaneous involvement of the same joint areas on both sides of the body;
- Rheumatoid nodules;
- Serum Rheumatoid Factor (RF)
- Radiographic changes. Criteria 1 through 4 must have been present for at least 6 weeks.
- Patients refractory or without complete response to DMARDs according to the Italian Guidelines for the clinical practice established by Italian Society of Rheumatology
- Patients naive to anti-TNF drugs
- Outpatients
Exclusion Criteria
Patients involved in controlled or interventional trials in the 12 previous months
Data sourced from ClinicalTrials.gov (NCT00794118). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.